Review of Biologics in Children With Rheumatic Diseases

Shabina Habibi; Athimalaipet V Ramanan


Int J Clin Rheumatol. 2012;7(1):81-93. 

In This Article

Anti-TNF-α Therapy

In a series on seven patients with TRAPS, all having active disease and either not responding to or requiring high doses of corticosteroids, etanercept was given at a dose of 25 mg subcutaneously twice weekly for 24 weeks.[60] Clinical activity as assessed by pain and overall well-being improved, and CRP levels decreased in five patients during follow-up. However one patient required a subsequent course after a 3-month washout period. This study demonstrated the short-term efficacy of etanercept in TRAPS. Etanercept has also demonstrated efficacy in the treatment of nephrotic syndrome and amyloidosis associated with TRAPS in case reports.[61,62] However case reports have also documented failure of anti-TNF-α therapy, especially infliximab, which may be complicated by a severe paradoxical inflammatory reaction.[63–66]


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: